Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

NCT02160756 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-56021927 Softgel Capsule
DRUG: JNJ-56021927 Tablet Formulation 1
DRUG: JNJ-56021927 Tablet Formulation 2
DRUG: JNJ-56021927 Tablet Formulation 3

Sponsor

Aragon Pharmaceuticals, Inc.